Sugi Predict

Sugi Predict / Compounds / SCHEMBL7523352

SCHEMBL7523352

SCHEMBL7523352

O=Cc1cccc(-c2ccsc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 5/20 0.51
▸ CYP2A6 P11509 3/20 0.50
▸ CYP2B6 P20813 2/20 0.50
▸ CYP2E1 P05181 1/20 0.50
▸ TRIM24 O15164 1/20 0.49
▸ TRIM33 Q9UPN9 1/20 0.49
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ PRMT6 Q96LA8 1/20 0.46
▸ PTPRC P08575 1/20 0.44
▸ KCNH2 Q12809 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CDK8 P49336 1/20 0.41
▸ BRD4 O60885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9175181 0.93 ERN1 (0.46) ERN1CYP2A6CYP2B6CYP2E1TRIM24
SCHEMBL9175193 0.93 ERN1 (0.46) ERN1CYP2A6CYP2B6CYP2E1TRIM24
SCHEMBL9454722 0.87 TRIM24 (0.49) ERN1CYP2A6CYP2B6CYP2E1TRIM24
SCHEMBL9171384 0.86 PRMT6 (0.52) ERN1CYP2A6CYP2B6CYP2E1TRIM24
SCHEMBL9259305 0.83 CCNB2 (0.49) ERN1CYP2A6CYP2B6CYP2E1PRMT6
SCHEMBL9259298 0.83 CCNB2 (0.49) ERN1CYP2A6CYP2B6CYP2E1PRMT6
SCHEMBL18002228 0.82 ERN1 (0.51) ERN1CYP2A6CYP2B6CYP2E1PTPRC
SCHEMBL18002045 0.82 CYP2A6 (0.62) ERN1CYP2A6CYP2B6CYP2E1TRIM24
SCHEMBL346974 0.82 TRIM24 (0.64) CYP2A6TRIM24TRIM33CA12CA1
SCHEMBL9455070 0.81 ERN1 (0.42) ERN1CYP2A6CYP2B6CYP2E1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-213951059-U Reaction device for preparing covalent organic framework through photo-initiation under vacuum condition 江阴创优新材料科技有限公司 2021-08-13 — — CN disclosed
CN-213611314-U Reaction device of covalent organic framework composite material based on photoinitiation 江阴创优新材料科技有限公司 2021-07-06 — — CN disclosed
CN-213160715-U Preparation facilities based on covalent organic skeleton of crystal multi-stage screening 苏州希夫安材料科技有限公司 2021-05-11 — — CN disclosed
CN-213160716-U Preparation facilities of high crystallinity covalence organic frame 苏州希夫安材料科技有限公司 2021-05-11 — — CN disclosed
CN-213160718-U Device based on continuous distillation preparation is covalence organic frame 苏州希夫安材料科技有限公司 2021-05-11 — — CN disclosed
CN-212893929-U Reaction device for preparing porous nano carbon material based on COFs material 苏州希夫安材料科技有限公司 2021-04-06 — — CN disclosed
US-10336743-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2019-07-02 — — US disclosed
CN-104011046-B Aminopyrimidine kinase inhibitors 嘉世高制药公司 2017-05-03 — — CN disclosed
US-9629840-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2017-04-25 — — US disclosed
EP-2776432-B1 AMINOPYRIMIDINE KINASE INHIBITORS JASCO PHARMACEUTICALS LLC (US) 2017-03-29 — — EP disclosed
EP-1187824-A2 NOVEL (2-SUBSTITUTED-5 - 3-THIENYL) -BENZYL]- 2- ( 2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS PIERRE FABRE MEDICAMENT (FR) 2002-03-20 — — EP disclosed
WO-2000058282-A2 NOVEL [(2-SUBSTITUTED-5 -[3-THIENYL) -BENZYL]-[2- ([2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS PIERRE FABRE MEDICAMENT (FR) 2000-10-05 — — WO disclosed
US-5444084-A Anticholesterol, antilipidemic agents BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-22 — — US disclosed
US-5439932-A Anticholesterol agents BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 — — US disclosed
EP-0609448-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVE HAVING SQUALENE EPOXIDASE INHIBITORY EFFECT AND USE THEREOF BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-08-10 — — EP disclosed
US-5306728-A Substituted amine derivatives having antihyperlipemia activity BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-04-26 — — US disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 — — US disclosed
EP-0448078-A2 Substituted amine derivatives having anti-hyperlipemia activity BANYU PHARMACEUTICAL CO., LTD. (JP) 1991-09-25 — — EP disclosed
EP-0395768-A1 SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-11-07 — — EP disclosed
CN-1042910-A The allylamine derivatives that replaces, their production method and application thereof BANYU PHARMA CO LTD (JP) 1990-06-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336743-B2 Aminopyrimidine kinase inhibitors PIM1, PIM2, PIM3 ERN1 572/4885CYP2A6 3286/4885CYP2B6 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.